Enterprise Value
89.94M
Cash
70.18M
Avg Qtr Burn
N/A
Short % of Float
14.73%
Insider Ownership
9.41%
Institutional Own.
45.74%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
OXAYDO (oxycodone HCl, USP) tablets Details Acute and chronic pain | Approved Quarterly sales | |
INDOCIN (indomethacin) Suppositories Details RA (Rheumatoid arthritis) | Approved Quarterly sales | |
Approved Quarterly sales | ||
SPRIX (ketorolac tromethamine) Nasal Spray Details Short-term Pain | Approved Quarterly sales | |
INDOCIN Oral Suspension Details RA (Rheumatoid arthritis) | Approved Quarterly sales | |
Cambia (diclofenac potassium) Details Migraines | Approved Quarterly sales |